Does Cigna Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant approved by the FDA for stroke prevention in nonvalvular atrial fibrillation, treatment and secondary prevention of deep vein thrombosis and pulmonary embolism, and short-term prophylaxis after hip or knee replacement surgery. [1] Because it requires no routine INR monitoring and carries a lower intracranial bleeding risk than warfarin, it has become one of the most prescribed anticoagulants in the United States.

Clinical Background on Apixaban

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against warfarin in patients with atrial fibrillation and found a 21% relative reduction in stroke or systemic embolism, a 31% reduction in major bleeding, and an 11% reduction in all-cause mortality. [2] These results, published in the New England Journal of Medicine, cemented apixaban as a first-line agent in the 2023 ACC/AHA/ACCP/HRS Atrial Fibrillation Guideline. [3]

The AMPLIFY trial (N=5,395) established apixaban's role in acute VTE treatment, showing non-inferiority to enoxaparin/warfarin for recurrent VTE while cutting major bleeding by 69%. [4] That evidence base explains why physicians fight hard to keep patients on apixaban when insurance creates obstacles.

Why Coverage Tier Matters Clinically

Patients who cannot afford their anticoagulant discontinue it. Discontinuation of apixaban in atrial fibrillation is associated with a significantly higher risk of ischemic stroke, as demonstrated in a 2021 JAMA Network Open cohort study of 9,769 AF patients where nonadherence was linked to a 3-fold increase in stroke hospitalization. [5] Coverage decisions are therefore not bureaucratic inconveniences. They carry direct clinical consequences.

How Cigna Formularies Are Structured

Cigna uses a tiered formulary system across its commercial, employer-sponsored, Medicare Advantage, and marketplace plans. Each tier carries a different cost-sharing level. Understanding where Eliquis sits tells you what you will pay before and after your deductible.

Tier Definitions on Typical Cigna Plans

| Tier | Drug Type | Typical Member Cost | |------|-----------|-------------------| | Tier 1 | Preferred generics | $5, $15/month | | Tier 2 | Non-preferred generics / preferred brands | $20, $50/month | | Tier 3 | Preferred brand-name drugs | $50, $120/month | | Tier 4 | Non-preferred brands | $100, $200+/month | | Tier 5 | Specialty drugs | 25 to 33% coinsurance |

Eliquis sits on Tier 3 in most Cigna commercial formularies and on Tier 4 in some. On Cigna Medicare Advantage Part D plans, it commonly lands on Tier 4, which carries higher cost-sharing before the out-of-pocket cap. [6] The exact tier depends on the specific plan year, the employer's benefit design, and whether your employer negotiated preferred placement.

How to Look Up Your Specific Plan

Cigna posts its drug lists at mycigna.com under "Coverage and Benefits," then "Prescription Drug List." You can search by drug name or NDC number. The FDA-approved apixaban NDC numbers are listed in the FDA's National Drug Code Directory. [7] Checking the formulary before filling is the single most reliable way to confirm your tier.

Does Cigna Require Prior Authorization for Eliquis?

Yes, prior authorization (PA) is required on many Cigna plans. The PA criteria typically require documentation of:

• A confirmed diagnosis (atrial fibrillation, DVT, PE, or post-surgical prophylaxis)
• CHA2DS2-VASc score of 2 or greater for AF patients (per AHA/ACC guideline thresholds) [3]
• Trial of or contraindication to warfarin, on plans with step-therapy requirements
• Renal function labs (serum creatinine) because dose adjustments apply when two of three criteria are met: age 80+, weight 60 kg or under, or creatinine 1.5 mg/dL or above [1]

Step Therapy: When Cigna Requires a Warfarin Trial

Some Cigna employer plans apply step therapy, requiring a documented trial of warfarin before approving apixaban. The 2018 New York State step therapy reform and subsequent federal guidance on Medicare Advantage step therapy have pushed back on these requirements for anticoagulants, but they persist on certain commercial plans. [8] If your plan has a step-therapy requirement, your physician can request an exception by documenting a clinical contraindication to warfarin, such as a history of labile INR, intolerance, or a patient-specific reason that makes INR monitoring unsafe.

How to File a Prior Authorization

Your prescribing physician submits a PA request through Cigna's eClinicalWeb portal or by fax. Cigna is required under the No Surprises Act and CMS rules to respond to urgent PA requests within 72 hours and standard requests within 3 business days for commercial plans. [9] For Medicare Advantage, the CMS 2024 final rule on prior authorization requires decisions within 7 calendar days for non-urgent requests and 72 hours for expedited requests. [10]

Required documentation usually includes office notes confirming the diagnosis, the prescribing physician's DEA/NPI number, the requested dose (2.5 mg or 5 mg twice daily), and supporting labs.

What Will You Actually Pay for Eliquis With Cigna?

Cost depends on four variables: your plan tier, whether your deductible has been met, whether a PA is approved, and whether you use a manufacturer coupon.

Before Your Deductible Is Met

If you have not yet hit your annual deductible, you likely pay the full negotiated rate, not a flat copay. The average Cigna negotiated price for a 60-tablet supply of Eliquis 5 mg (one month) ranges from approximately $480 to $560 based on pharmacy benefit manager data, though exact contracted rates are not public. [11] This means early in the plan year, before the deductible resets, monthly costs can exceed $500.

After Your Deductible Is Met

Once your deductible is satisfied, you move to cost-sharing based on your tier. On a typical Cigna plan with Eliquis on Tier 3, you might pay $85 to $120 per 30-day fill. On a Tier 4 placement, that rises to $150 to $225 per month.

The BMS/Pfizer Savings Card

Bristol-Myers Squibb and Pfizer offer a co-pay assistance card that can reduce Eliquis cost to $10 per 30-day supply for eligible commercially insured patients. [12] This card does NOT work for Medicare, Medicaid, or government-funded plan enrollees. It applies only to commercial (employer or marketplace) insurance. Patients can enroll at the manufacturer's savings program website. The card typically covers up to $3,300 per year in savings.

Out-of-Pocket Maximum Protection

All ACA-compliant Cigna plans cap out-of-pocket spending. For 2025, the ACA maximum out-of-pocket limit is $9,450 for individual coverage and $18,900 for family coverage. [13] Once you reach that cap, Cigna covers 100% of covered drug costs, including Eliquis. For patients on chronic anticoagulation, tracking cumulative spending from January onward is worth doing.

Generic Apixaban: The Most Important Recent Development

Generic apixaban became available in the United States in April 2023 following the expiration of Bristol-Myers Squibb's primary patents. [14] This is the single biggest change to Eliquis affordability in years.

How Much Does Generic Apixaban Cost?

Generic apixaban 5 mg (60 tablets) lists for approximately $25 to $80 at major retail pharmacies with GoodRx or similar discount programs, compared to over $500 for brand Eliquis without insurance. [15] Many Cigna formularies now place generic apixaban on Tier 1 or Tier 2, making it dramatically cheaper than brand Eliquis for most members.

Is Generic Apixaban Bioequivalent?

Yes. The FDA requires generic drugs to demonstrate bioequivalence, meaning the generic must deliver the same active ingredient at the same dose with the same rate and extent of absorption within a narrow confidence interval, typically 80 to 125% of the reference listed drug. [16] The FDA's guidance on bioequivalence standards for anticoagulants applies the same criteria as for other narrow therapeutic index drugs. [16] Switching from brand Eliquis to generic apixaban does not require a new prior authorization in most cases, but verify with your pharmacist.

Switching From Brand to Generic: A Clinical Decision Framework

Before switching, your physician should confirm:

1. Your current Eliquis dose (2.5 mg or 5 mg twice daily) matches the available generic strength.
2. No active bleeding event or recent dose adjustment is pending.
3. Your pharmacy can source the generic (some smaller pharmacies had supply constraints in 2023 to 2024).
4. Your Cigna plan has updated its formulary to list generic apixaban (check at mycigna.com).

If all four conditions are met, a simple prescription change to "apixaban" (without brand specification) allows the pharmacist to dispense the generic and bill it at the lower tier rate.

Alternatives to Eliquis Covered by Cigna

If prior authorization is denied or costs remain prohibitive even with the savings card, several alternatives exist. Coverage tier and clinical appropriateness determine which option fits.

Other Direct Oral Anticoagulants

• Rivaroxaban (Xarelto): Once-daily dosing; FDA-approved for AF, VTE, and prophylaxis. [17] Cigna formulary placement varies. The ROCKET-AF trial (N=14,264) showed rivaroxaban non-inferior to warfarin for stroke prevention in AF. [18]
• Dabigatran (Pradaxa): A direct thrombin inhibitor approved for nonvalvular AF and VTE treatment. [19] The RE-LY trial (N=18,113) showed dabigatran 150 mg superior to warfarin for stroke prevention but with higher GI bleeding rates. [20]
• Edoxaban (Savaysa): Less commonly prescribed, but FDA-approved for AF and VTE treatment after 5 to 10 days of parenteral anticoagulation. [21]

Warfarin as Step Therapy Fallback

Warfarin (generic, very inexpensive) remains an option for patients without a contraindication, though it requires regular INR monitoring and has a narrower therapeutic window. The 2023 ACC/AHA AF guideline rates DOACs as preferred over warfarin for nonvalvular AF except in specific circumstances such as moderate-to-severe mitral stenosis or mechanical heart valves. [3]

How to Appeal a Cigna Denial for Eliquis

If Cigna denies your PA or step-therapy exception request, you have formal appeal rights. The ACA and ERISA both grant the right to internal and external appeals.

Internal Appeal

File within 180 days of receiving the denial notice. Your physician should submit:

• A letter of medical necessity citing ARISTOTLE [2] or AMPLIFY [4] trial data
• Documentation of any warfarin contraindication or failed INR stability
• Your CHA2DS2-VASc score if applicable
• Any relevant lab values (renal function, CBC)

Cigna must respond to an internal appeal within 30 days for a pre-service denial and 60 days for a post-service denial under ERISA rules. [22]

External Review

If the internal appeal fails, you can request an independent external review through your state's insurance commissioner or through the federal external review process for self-funded plans. The external reviewer is independent of Cigna. CMS data show that patients win external reviews at a rate of approximately 40% for prescription drug denials. [23]

State Protections

Several states have enacted step-therapy protection laws requiring insurers to grant exceptions for patients already stabilized on a medication. As of 2024, 36 states have some form of step-therapy reform law on the books. [24] If you are already stable on Eliquis and Cigna is attempting to force a switch, your physician can invoke these protections in applicable states.

Cigna Medicare Advantage and Eliquis: Special Considerations

Medicare Advantage Part D formularies operate under CMS rules, which differ from commercial plan rules in important ways.

Medicare Part D Coverage Gap Changes

The Inflation Reduction Act of 2022 eliminated the Medicare Part D coverage gap (the "donut hole") effective January 1, 2025, and capped out-of-pocket costs for Part D enrollees at $2,000 per year. [25] This is a major change for Cigna Medicare Advantage members on Eliquis, many of whom previously faced several hundred dollars per month in the coverage gap phase.

Extra Help / Low Income Subsidy

Medicare beneficiaries with limited income and resources may qualify for the Low Income Subsidy (LIS), also called Extra Help, which reduces or eliminates Part D cost-sharing including for Eliquis. [26] As of 2023, CMS expanded automatic LIS enrollment eligibility.

Medicare Coverage of INR Monitoring vs. DOAC Costs

Warfarin users have Medicare-covered INR monitoring visits. DOAC users, including those on Eliquis, do not require monitoring labs, but the drug cost itself falls under Part D rather than Part A or B. This makes formulary tier and out-of-pocket caps particularly consequential for Medicare Advantage members.

Practical Steps to Minimize Your Eliquis Cost With Cigna

1. Ask for generic apixaban first. At a Tier 1 or 2 generic price, it may cost under $30 per month with Cigna, compared to $100+ for brand Eliquis.
2. Apply for the BMS/Pfizer savings card if you have commercial (non-government) insurance.
3. Have your physician submit a prior authorization with complete clinical documentation before your first fill to avoid paying full price at the pharmacy.
4. Request a formulary exception if Cigna places Eliquis on a non-preferred tier and generic apixaban is unavailable or clinically unsuitable.
5. Track your annual out-of-pocket spending. Once you hit your plan's maximum, Cigna covers 100% of costs.
6. Check the Cigna formulary each January. Formularies change annually. Eliquis' tier may shift, and generic apixaban placement improves most years.
7. Consider 90-day supplies. Many Cigna plans offer lower per-day cost-sharing for 90-day mail-order fills versus 30-day retail fills.

What Physicians and Guidelines Say About Keeping Patients on DOACs

The 2023 ACC/AHA/ACCP/HRS guideline on atrial fibrillation management states: "For patients with AF and elevated stroke risk, direct oral anticoagulants (DOACs) are recommended over warfarin in the absence of moderate-to-severe mitral stenosis or mechanical heart valves (Class I, Level of Evidence A)." [3]

The American College of Chest Physicians 2021 guideline on VTE antithrombotic therapy similarly states: "For patients with DVT or PE who are treated with anticoagulation, we suggest a DOAC over VKA therapy (Grade 2B)." [27] These strong guideline positions give your physician solid footing to push back on any step-therapy requirement that tries to substitute warfarin.